Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.59
+0.16 (1.04%)
Aug 5, 2025, 4:00 PM - Market closed
Iteris Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
1.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | 102 | 19 | 22.89% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MESO News
- 19 days ago - Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 5 weeks ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 5 weeks ago - Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure - GlobeNewsWire
- 7 weeks ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 2 months ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire
- 3 months ago - Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials - Seeking Alpha
- 3 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 - GlobeNewsWire
- 3 months ago - Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board - GlobeNewsWire